Grant Sean 4

What Happened
Sean Grant, Chief Financial Officer of Vera Therapeutics (VERA), received equity awards on February 4, 2026: 25,000 shares granted (reported as acquired at $0.00) and 50,000 derivative shares (reported as acquired at $0.00), for a reported transaction value of $0. These are grants/awards under the issuer's equity plan, not open-market purchases or sales.

Key Details

• Transaction date: February 4, 2026; Form 4 filed February 6, 2026 (timely within the usual two-business-day reporting window).
• Reported items: 25,000 shares (acquired at $0.00) and 50,000 derivative shares (acquired at $0.00). Total reported cash paid: $0.
• Shares owned after transaction: not specified in the data provided here—see the filed Form 4 for aggregate beneficial ownership amounts.
• Footnotes of note:
  • F1: The derivative grant represents RSUs that vest one-fourth on each of Feb 20, 2027, 2028, 2029 and 2030, subject to continued service.
  • F2: The reporting person’s holdings include 893 shares acquired under the 2021 ESPP on Sept 12, 2025.
  • F3: Separately referenced stock option holdings vest 1/48th on March 4, 2026 and monthly thereafter (these are vesting schedule details for other option grants, not the Feb 4 RSU award).
• Transaction code: A = Award/Grant.

Context
These entries are compensation awards (restricted shares and RSUs). RSUs are derivative securities that convert to common stock only as they vest per the schedule in F1; they are not immediate open-market purchases. Such grants are common executive compensation and should be interpreted as awarded compensation rather than a direct market endorsement or sale.